Zylox-Tonbridge Medical Technology Management
Management criteria checks 3/4
Zylox-Tonbridge Medical Technology's CEO is Jonathon Zhao, appointed in Nov 2012, has a tenure of 12.92 years. total yearly compensation is CN¥13.67M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 13.32% of the company’s shares, worth HK$1.06B. The average tenure of the management team and the board of directors is 4.8 years and 4.6 years respectively.
Key information
Jonathon Zhao
Chief executive officer
CN¥13.7m
Total compensation
| CEO salary percentage | 21.95% |
| CEO tenure | 12.9yrs |
| CEO ownership | 13.3% |
| Management average tenure | 4.8yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Not Lagging Industry On Growth Or Pricing
Sep 24
The Return Trends At Zylox-Tonbridge Medical Technology (HKG:2190) Look Promising
Aug 13Here's Why Shareholders May Want To Be Cautious With Increasing Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) CEO Pay Packet
May 23Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
May 09Why Investors Shouldn't Be Surprised By Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) 37% Share Price Surge
May 07Returns Are Gaining Momentum At Zylox-Tonbridge Medical Technology (HKG:2190)
Apr 17Optimistic Investors Push Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Up 30% But Growth Is Lacking
Mar 19Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | CN¥153m |
| Mar 31 2025 | n/a | n/a | CN¥126m |
| Dec 31 2024 | CN¥14m | CN¥3m | CN¥100m |
| Sep 30 2024 | n/a | n/a | CN¥63m |
| Jun 30 2024 | n/a | n/a | CN¥26m |
| Mar 31 2024 | n/a | n/a | -CN¥27m |
| Dec 31 2023 | CN¥17m | CN¥3m | -CN¥79m |
| Sep 30 2023 | n/a | n/a | -CN¥101m |
| Jun 30 2023 | n/a | n/a | -CN¥124m |
| Mar 31 2023 | n/a | n/a | -CN¥119m |
| Dec 31 2022 | CN¥21m | CN¥3m | -CN¥114m |
| Sep 30 2022 | n/a | n/a | -CN¥135m |
| Jun 30 2022 | n/a | n/a | -CN¥155m |
| Mar 31 2022 | n/a | n/a | -CN¥178m |
| Dec 31 2021 | CN¥16m | CN¥2m | -CN¥200m |
| Sep 30 2021 | n/a | n/a | -CN¥168m |
| Jun 30 2021 | n/a | n/a | -CN¥135m |
| Mar 31 2021 | n/a | n/a | -CN¥118m |
| Dec 31 2020 | CN¥10m | CN¥1m | -CN¥100m |
| Dec 31 2019 | CN¥1m | CN¥746k | -CN¥67m |
Compensation vs Market: Jonathon's total compensation ($USD1.92M) is above average for companies of similar size in the Hong Kong market ($USD432.00K).
Compensation vs Earnings: Jonathon's compensation has been consistent with company performance over the past year.
CEO
Jonathon Zhao (57 yo)
Dr. Zhong Zhao, also known as Jonathon, was Director of Avinger, Inc. from March 04, 2024 to February 10, 2025. He is Founder of Zylox-Tonbridge Medical Technology Co., Ltd. and serves as its Chairman sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.9yrs | CN¥13.67m | 13.32% HK$ 1.1b | |
| Senior VP of Sales & Marketing and Executive Director | no data | CN¥4.98m | 0.24% HK$ 18.7m | |
| Senior VP | no data | CN¥6.18m | 0.21% HK$ 16.6m | |
| CFO & Joint Company Secretary | 4.8yrs | no data | no data | |
| Joint Company Secretary | 3.1yrs | no data | no data |
Experienced Management: 2190's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.9yrs | CN¥13.67m | 13.32% HK$ 1.1b | |
| Senior VP of Sales & Marketing and Executive Director | 7.6yrs | CN¥4.98m | 0.24% HK$ 18.7m | |
| Senior VP | 6.8yrs | CN¥6.18m | 0.21% HK$ 16.6m | |
| Independent Non-Executive Director | 4.6yrs | CN¥200.00k | no data | |
| Non-Executive Director | 5yrs | no data | no data | |
| Non Executive Director | 3.4yrs | no data | no data | |
| Independent Non-Executive Director | 4.6yrs | CN¥200.00k | no data | |
| Employee Supervisor | 4.6yrs | no data | 0.027% HK$ 2.2m | |
| Supervisor | 3.4yrs | no data | 0.022% HK$ 1.7m | |
| Chairman of the Board of Supervisors | 1.9yrs | no data | 0.0077% HK$ 610.3k | |
| Independent Non-Executive Director | 1.3yrs | CN¥117.00k | no data |
Experienced Board: 2190's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 18:44 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zylox-Tonbridge Medical Technology Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Gao | China International Capital Corporation Limited |
| Ziran Gu | Citic Securities Co., Ltd. |
| Shuo Song | Citic Securities Co., Ltd. |